Novartis AG

Most Recent

  • uploads///Graph
    Miscellaneous

    Teva Can Benefit by Acquiring Allergan Generics

    The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

    By Margaret Patrick
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Spark pipeline
    Company & Industry Overviews

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Modest Revenue Growth in Fiscal 2016

    Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success

    On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Recommend for Novartis in March 2018

    As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Lilly’s Total Returns Are Lower than Some Pharma ETFs

    The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    How Gilead Sciences’ Gross Margin Outshines Its Peers

    Despite a year-over-year (or YoY) drop in revenues in 2Q16, Gilead Sciences (GILD) managed to earn gross margins of about 92%.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why the Majority of Analysts Deem Novartis a ‘Buy’

    Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

    By Mike Benson
  • uploads///Pfizer revenues
    Company & Industry Overviews

    How Did Pfizer Perform in 3Q17?

    In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Eylea
    Earnings Report

    Eylea’s Net Sales in the US Jumped in 4Q15, but Was It High Enough?

    Eylea, the leading product in Regeneron Pharmaceuticals’s (REGN) portfolio, fetched $746 million during the fourth quarter of 2015 in the US.

    By Jillian Dabney
  • uploads///Biogen Analysts Recommendation
    Company & Industry Overviews

    What Analysts Recommend for Biogen in June 2017

    In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

    By Daniel Collins
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    How Biogen’s Tysabri and Zinbryta Performed in 1Q17

    In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Gardasil and What It Could Mean

    Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Dermatology Business Felt Pricing Pressure in 2016

    Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously marketed its dermatology drugs through specialty pharmacies, the company now distributes its products through Walgreens. To learn about the company’s current distribution model, please refer to How Valeant Plans […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Amgen’s Plans to Penetrate the Migraine Segment

    Amgen and Novartis are exploring an investigational drug that is a CGRP antibody, AMG 334, for the treatment of episodic and chronic migraine headaches.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Siliq May be a Strong Growth Driver for Valeant in 2017

    Siliq growth trends On February 15, 2017, the FDA approved injectable biologic therapy Siliq (brodalumab) as a treatment option for moderate-to-severe plaque psoriasis patients. Siliq is for psoriasis patients eligible for systemic therapy or phototherapy, and are not responding sufficiently or have stopped responding to these treatment options. To learn more about Siliq, please refer to What Are […]

    By Margaret Patrick
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    International Segment: Key Driver of VRX’s Revenue Growth in 2016

    In the first nine months of 2016, the Bausch + Lomb/International segment reported revenues of ~$3.4 billion, which equals year-over-year (or YoY) growth of ~0.4%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Eylea Could Face Tough Competition in 2016

    In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s to Be Expected from Novartis’s 3Q16 Earnings?

    Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.

    By Mike Benson
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Diversification
    Macroeconomic Analysis

    Are You Thinking about Diversifying Your Portfolio?

    Geographical diversification allows your portfolio to keep earning returns in case your primary geography has not been doing well.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Expected to See a Fall in Its Profit Margins in 2017

    Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

    By Margaret Patrick
  • uploads///Eylea sales
    Earnings Report

    Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018?

    Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

    By Jillian Dabney
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Amgen: Exploring Opportunities in the Bone Segment

    Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.

    By Margaret Patrick
  • uploads///ibrance
    Company & Industry Overviews

    Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

    Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

    By Jillian Dabney
  • uploads///syringe _
    Company & Industry Overviews

    Teva’s Granix Gets FDA Approval for Expanded Indication

    Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

    By Sarah Collins
  • Healthcare

    Why AstraZeneca’s oncology pipeline is attractive to Pfizer

    Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.

    By Samantha Nielson
  • uploads///Eylea
    Company & Industry Overviews

    How Regeneron Is Working to Maintain Eylea’s Dominance

    Regeneron’s (REGN) flagship product, Eylea (Aflibercept), was launched in the US in November 2011.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Valuation Report Card: How Did It Score?

    The fundamental factors affecting stock prices and valuation include the performance of growth platforms as well as the exclusivity of blockbuster drugs.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///sales estimates
    Company & Industry Overviews

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Novartis Will Report Its 4Q15 Earnings on January 27

    Novartis is set to release its 4Q15 and full-year 2015 earnings on January 27, 2016. Analysts estimate an EPS of $1.32 for 4Q15.

    By Mike Benson
  • uploads///GSK CONSUMER HEALTHCARE MILESTONES
    Company & Industry Overviews

    GlaxoSmithKline Buys Novartis’s Stake in Joint Venture

    On March 27, 2018, GlaxoSmithKline (GSK) announced an agreement with Novartis (NVS) to buy Novartis’s stake in their consumer healthcare joint venture.

    By Sarah Collins
  • uploads///pharma division performance
    Earnings Report

    Sales Performance Analysis of Roche’s Pharmaceuticals Division

    Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

    By Jillian Dabney
  • uploads///share price
    Earnings Report

    Understanding Regeneron’s Share Price Movement after Its 4Q15 Results

    Regeneron Pharmaceuticals (REGN) earned $1.1 billion in 4Q15, which translates to a 37% YoY (year-over-year) sales growth.

    By Jillian Dabney
  • uploads///pill _
    Earnings Report

    What Analysts Recommend for Mylan before Q2 2018 Earnings

    Mylan (MYL) plans to release its Q2 results on August 8. Thirteen of the 20 analysts covering the stock have given it a “buy” or “strong buy.”

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Novartis Focuses on Portfolio Prioritization to Boost Profitability

    To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

    By Margaret Patrick
  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    What to Expect from Johnson & Johnson’s 4Q15 Earnings

    Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Entering Migraine Market Won’t Be Easy for Novartis, Amgen

    Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.

    By Margaret Patrick
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///Eylea
    Earnings Report

    What Drove Regeneron’s 3Q16 Performance?

    In fiscal 3Q16, Regeneron Pharmaceuticals (REGN) recorded revenue amounting to $1.2 billion and net product sales amounting to $857 million.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Share of the US Generics Market Could Boost Its Stock

    Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.

    By Margaret Patrick
  • uploads///pill _
    Company & Industry Overviews

    FDA Rejects Mylan’s Generic Advair Again, Stock Falls

    On June 13, Mylan (MYL) announced that the FDA did not approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    How Merial Contributes to Sanofi’s Growth

    Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.

    By Mike Benson
  • uploads///US Investment Grade Bond Fund Flows
    Company & Industry Overviews

    Investment-Grade Bond Funds Witnessed Inflows

    The flows into investment-grade bond funds were positive for the week ending November 18. Investment-grade bond funds saw net inflows of $945.0 million.

    By Lynn Noah
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Key Focus: Oncology

    AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.

    By Mike Benson
  • uploads///growth of generics
    Company & Industry Overviews

    Rx for Growth? Why Generic Drugs Are Gaining Traction

    Rx for Growth? The trillion-dollar pharmaceutical industry has historically been dominated by a few major companies that create and supply the most important branded prescriptions on the market. Recent trends, however, point to the growth of the newest pharma blockbusters: generics. Today, approximately 60% of Americans take prescription drugs;[1. “Trends in Prescription Drug Use Among […]

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: Innovative Medicines Segment

    Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

    By Mike Benson
  • uploads///Yescarta
    Company & Industry Overviews

    What Else Could Drive Gilead’s Long-Term Growth?

    In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

    By Daniel Collins
  • uploads///Eliquis and Sprycel
    Company & Industry Overviews

    Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

    In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

    By Daniel Collins
  • uploads///tablets _
    Earnings Report

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. Here’s what you need to know.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be Strong Growth Driver for Sanofi in the Future

    Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q16 Estimates: Innovative Medicines Segment

    The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///COPAXONE
    Company & Industry Overviews

    Teva’s Copaxone Maintains Market Share amid Intense Competition

    In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

    By Sarah Collins
  • uploads///Recent wins
    Earnings Report

    Brodalumab, Oral Relistor among Valeant’s Recent Wins

    Valeant’s (VRX) recent wins include the FDA’s advisory committee vote in favor of approving brodalumab for the indication of mild to moderate psoriasis.

    By Jillian Dabney
  • uploads///gks
    Earnings Report

    How Has Aquinox Performed Compared to Peers?

    Aquinox has a positive future outlook and will likely continue to better its performance in the near future.

    By Gabriel Kane
  • uploads///Chart  NVO
    Miscellaneous

    Performance of Novo Nordisk Stock in 2Q17

    Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///long term strtegy
    Earnings Report

    Inside Roche’s Strategy to Offset Revenue Declines

    Roche’s big three contributors include MabThera/Rituxan, Herceptin, and Avastin, which accounted for 14.7%, 13.9% and 13.7% of revenues in fiscal 1Q16.

    By Jillian Dabney
  • uploads///checklist _
    Healthcare

    Major M&A Deals in Pharmaceutical Sector in May and June

    On June 1, GlaxoSmithKline (GSK) completed the buyout of a 36.5% stake in Novartis (NVS) in a consumer healthcare joint venture.

    By Mike Benson
  • uploads///Animal Health Segment
    Earnings Report

    How Did Merial Contribute to Sanofi’s 2Q15 Growth?

    Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.

    By Mike Benson
  • uploads///portfolio
    Company & Industry Overviews

    Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst

    Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

    By Jillian Dabney
  • uploads///novartis
    Fund Managers

    Maverick Capital Increases Stake in Novartis

    Maverick Capital increased its position in Novartis (NVS) by more than $22 million in stock. It represented 0.75% of the fund’s total portfolio in 4Q14.

    By Patricia Garner
  • uploads///pills _
    Company & Industry Overviews

    Teva Announces First-to-File Launch of Generic Cialis

    Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

    By Sarah Collins
  • uploads///medical _
    Earnings Report

    Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results

    Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Why Eli Lilly Expects 2Q17 Revenue Growth

    As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.

    By Mike Benson
  • uploads///Merck Performance
    Company & Industry Overviews

    How Merck Is Expected to Perform in 2017

    In 1Q17, Merck (MRK) generated revenues of ~$9.4 billion, which reflected 1% YoY growth. Merck expects its GAAP net revenues in fiscal 2017 to reach $39.1 billion–$40.3 billion.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Inside Novartis’s Eye Care Performance in 4Q16

    Alcon, NVS’s eye care segment, saw its 4Q16 revenues fall ~2% to ~$1.4 billion, including no change in sales but a -2% impact from foreign exchange.

    By Mike Benson
  • uploads///Chart  Ph
    Company & Industry Overviews

    Why GlaxoSmithKline’s Pharmaceuticals Business Grew

    GlaxoSmithKline is a major shareholder of ViiV Healthcare. Its HIV products reported revenue of 1.12 billion pounds during 2Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Which of Amgen’s Drugs Could Witness Muted Growth in 2016?

    Wall Street analysts have projected that Xgeva’s revenues will reach about $1.6 billion in 2016, which represents a YoY growth of about 12.3% for Amgen.

    By Margaret Patrick
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    What Analysts Expect from Pfizer in the Years to Come

    Due to Pfizer’s (PFE) strong Innovative Products business and product pipeline, analysts estimate that it will generate $0.54 in earnings per share in 1Q16.

    By Mike Benson
  • uploads///Costs
    Earnings Report

    Johnson & Johnson’s Profitability Improves in 2Q15

    Johnson & Johnson’s net profit margin improved to 25.4% for 2Q15 compared to 22.2% for 2Q14 due to the divestiture of some low profitability products and improved sales of high profitability products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Sanofi’s Consumer Healthcare and Generics Franchises

    Sanofi’s (SNY) Consumer Healthcare franchise’s products include Allegra, Doliprane, and Nasacort. The segment reported a 3.1% decline in revenues at 905 million euros in 1Q16, compared to its 1Q15 revenues.

    By Mike Benson
  • uploads///Article
    Earnings Report

    Why Novartis’s Revenues Declined Marginally

    In 2Q15, Novartis (NVS) achieved revenues of $12.69 billion, an increase of ~6.3% over 1Q15.

    By Mike Benson
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///johnson and johnson earnings
    Earnings Report

    Will Johnson & Johnson’s Q1 Earnings Improve?

    Johnson & Johnson (NYSE:JNJ) stock has declined by 3.2% since the beginning of 2020. However, the stock has fared better than the broader market.

    By Sirisha Bhogaraju
  • uploads///Zoetis Business Model
    Financials

    Zoetis: An attractive business model

    Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”

    By Samantha Nielson
  • Financials

    Cyclical factors that contributed to unemployment in the Eurozone

    Cyclical unemployment is a product of business cycles. A business cycle refers to periods of expansion or recession. In Europe’s case, weak gross domestic product (or GDP) data across the 18-nation economy continues to reflect the Eurozone’s weakness.

    By Surbhi Jain
  • Financials

    Sovereign debt crisis contributed to the Eurozone’s unemployment

    A sovereign debt crisis is a situation where economic and financial problems are caused by a country’s inability to pay its public debt. This usually happens when a country reaches critically high debt levels and suffers from low economic growth.

    By Surbhi Jain
  • Financials

    Structural factors that contributed to unemployment in the Eurozone

    Structural unemployment occurs for numerous reasons. It’s usually due to a lack of requisite job skills among workers. It can also be caused by a lack of workers’ willingness to work because of existing low wage levels.

    By Surbhi Jain
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Expects Peak Sales of $7 Billion for Imbruvica

    AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

    By Margaret Patrick
  • uploads///Ignyta Pipeline
    Company & Industry Overviews

    Ignyta’s Drug Pipeline

    Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

    By Kenneth Smith
  • uploads///Ignyta RD Expenses
    Company & Industry Overviews

    Inside Ignyta’s Financial Performance

    Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.